Allergan Restasis Launch Set For April Following Approval Of Dry Eye Drug
Executive Summary
Allergan's chronic dry eye disease agent Restasis (cyclosporine ophthalmic emulsion 0.5%) will be available in early April, following FDA approval Dec. 23
You may also be interested in...
Inspire’s Diquafosol Is “Approvable” For Dry Eye; FDA Requests Efficacy Data
Inspire Pharmaceuticals hopes that supplemental Phase III data on the dry eye agent diquafosol (INS 365) will help address efficacy questions raised by FDA in a Dec. 19 "approvable" letter
Inspire’s Diquafosol Is “Approvable” For Dry Eye; FDA Requests Efficacy Data
Inspire Pharmaceuticals hopes that supplemental Phase III data on the dry eye agent diquafosol (INS 365) will help address efficacy questions raised by FDA in a Dec. 19 "approvable" letter
Tidbits From The Fourth Quarter Calls, In Brief
AstraZeneca Prilosec generic erosion: AstraZeneca's Prilosec holds 47% share of total prescriptions following generic omeprazole entry in late 2002, CFO Jon Symonds says on Jan. 30 investor call. "We must, of course, be cautious with only six weeks of data available...but it's clear that the erosion rate is significantly less than that observed with either Prozac or Zestril at a similar stage, seemingly consistent with Kudco's inability to fully supply the market." Schwarz' subsidiary Kudco is distributing generic Prilosec on a limited basis due to supply constraints (1"The Pink Sheet" Dec. 16, 2002, p. 30)....Nexium ramp-up: Nexium total prescription share is over 20%, up more than eight percentage points in 2002. Share of total scripts written by gastrointestinal specialists is more than 27%...